Gene transfer to blood vessels is remarkably effective in altering vasomotor function, and has proven to be a useful tool for studying vascular biology. Gene therapy for cardiovascular diseases is an attractive new approach, which will be used initially for diseases in which pharmacologic approaches are not effective. Preliminary data suggest that two possible targets for gene therapy are prevention of cerebral vasospasm after subarachnoid hemorrhage and treatment of pulmonary hypertension. Perhaps, as better vectors are developed, common clinical problems such as hypertension and hypercholesterolemia also may become targets for gene therapy. Am J Hypertens 2001;14: 28S-32S
G
ene transfer to blood vessels was first reported a little more than a decade ago. 1 There have been enormous technical advances since then, and the approach is used by investigators in a variety of disciplines. Substantial obstacles remain, however, both for experimental uses of gene transfer and especially when the objective is gene therapy.
In this review, we describe methods for gene transfer and studies to test efficacy of gene transfer to blood vessels. One way that we tested efficacy was to examine effects of gene transfer of endothelial nitric oxide synthase (eNOS) to the aorta of eNOS-deficient mice. We also describe two examples of surprising effects of gene transfer to blood vessels that have helped us to better understand vascular biology.
We also describe clinical states that may be amenable to gene therapy. It is likely that gene therapy initially will be used for clinical conditions in which pharmacologic approaches are not effective. When a vasoactive drug or peptide is useful for a clinical condition or disease, it seems most likely that the risk-to-benefit ratio for gene therapy will not be acceptable. Nevertheless, there are several major diseases and conditions that are resistant to standard treatment, and also some common diseases in which gene therapy may eventually be useful. We describe two possible targets for gene therapy: prevention of cerebral vasospasm after subarachnoid hemorrhage (SAH) and treatment of pulmonary hypertension.
Gene Transfer to Blood Vessels
When we describe effects of gene transfer of eNOS to blood vessels, one might ask, "Why not simply give nitric oxide (NO) or a NO-donor to study effects on blood vessels?" This certainly is an appropriate question, because several steps are required for successful gene transfer of eNOS. One reason why gene transfer may be preferable to simply administering the gene product is that different isoforms of an enzyme can be examined with gene transfer. Thus, eNOS or inducible NOS (iNOS) can be given by gene transfer to examine effects and regulation of different isoforms of NOS. Second, specific cells in vessels can be transduced by gene transfer. For example, one can transduce only the endothelium or adventitia. This is particularly attractive because increasing evidence suggests that adventitia, as well as endothelium, plays an important role in vascular biology. 2 In our studies, we have used a replication-deficient recombinant adenovirus for gene transfer. We use an adenoviral vector because it is generally far more effective than other vectors in gene transfer to the slowly dividing cells of blood vessels. 3 We have made most of the recombinant viruses that we have used in our experiments by deletion of the parts of the viral genome that are necessary for replication, and then insertion of the genes of interest into the regions of the viral genome that have been deleted. We use a promoter that will give expression for the length of time that we prefer for each experiment. Although the host immune response determines duration of transgene expression, past a week, a promoter can be used to obtain intense expression that peaks within a day, or less intense expression that peaks in a few days. 4 We then test the new recombinant adenovirus in tissue culture to confirm that the transgene product is being made.
We generally begin studies with a new recombinant virus by testing effects in rings of blood vessels in tissue culture. An important finding was that gene transfer of a reporter gene to blood vessels in tissue culture can produce a large amount of the transgene product while having little effect on either contraction or endothelium-dependent relaxation of the vessels. 5, 6 It is also of interest that transduction of adventitia, even in the absence of endothelium, alters vasomotor responses. 5, 6 Gene transfer to blood vessels in vivo usually is accomplished either by stopping blood flow within the vessel for many minutes to allow viral infection of the endothelium, or by injection of the vector at very high levels of pressure. 7, 8 One of our goals was to develop a method to allow gene transfer to intracranial blood vessels, and clearly neither of the standard methods would be appropriate. Therefore, we developed a method that did not require intravascular injection of the vector and high pressure and did not require interruption of blood flow. Adenoviral vectors are injected into the cisterna magna, which allows the virus to diffuse through cerebrospinal fluid (CSF), and results in expression of the reporter gene in adventitia and perivascular tissues (Fig. 1) . 9 We and other researchers have also used this extravascular approach for gene transfer to the carotid and femoral arteries by injecting the virus into the vascular sheath. 10 A potential limitation of adventitial expression of transgene products was that, without transduction of endothelium or smooth muscle, there might be little effect on vasomotor tone. We and other investigators found, however, that when a gene with a diffusible product (such as NO or calcitonin gene-related peptide [CGRP] ) is transferred to adventitia, there is marked alteration of vasomotor function, because the gene product readily diffuses into the underlying smooth muscle. 5, 6, 11 This extravascular approach in vivo has been used to alter function in several studies. In one experiment, eNOS was applied extravascularly to the carotid sinus in vivo, with substantial alteration of baroreceptor function. 12 The method was also used to alter vasomotor function of intracranial cerebral blood vessels. 13 
Effects of Gene Transfer on Vasomotor Function
An important question is, how effective is gene transfer in alteration of vascular function? To test efficacy, we studied effects of gene transfer of eNOS to eNOS-deficient mice. A striking finding was that in eNOS-deficient mice, vascular relaxation to acetylcholine, or A23187 could be restored to essentially normal by gene transfer of eNOS. 14 Relaxation of the aorta to acetylcholine or A23187 was absent in eNOS-deficient mice, and 24 h after gene transfer of eNOS in vitro, responses were restored to normal. Thus, this is a unique way to study effects of eNOS in blood vessels in the absence of endogenous eNOS, and it also indicates that gene transfer to blood vessels is remarkably efficacious.
For many years we have studied mechanisms of alteration of endothelium-dependent relaxation in the presence of disease states. Numerous studies have shown that re- 
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sponses to acetylcholine and other NO-dependent vasodilators are markedly impaired by hypertension, atherosclerosis, and diabetes. A major mechanism of impairment of responses is superoxide, which is generated in the presence of these diseases (Fig. 2) , which inactivates NO and thus impairs relaxation to acetylcholine.
Because of the pivotal role of superoxide in impairment of vasomotor responses, we anticipated that gene transfer of superoxide dismutase (SOD) would improve relaxation. Furthermore, we anticipated that gene transfer of eNOS would fail to improve relaxation, based on the assumption that generation of more NO would be inactivated by superoxide. We found, however, that gene transfer of CuZn-SOD or EC-SOD failed to improve responses to acetylcholine in vessels from animals that received angiotensin II, were atherosclerotic, or were diabetic. [15] [16] [17] Furthermore, and of some surprise to us, gene transfer of eNOS improved relaxation to acetylcholine in the presence of each of these disease states. 15, 17, 18 Several factors may contribute to failure of gene transfer of CuZn-SOD and EC-SOD and efficacy of gene transfer of eNOS, in improving vasomotor function in vessels with elevated levels of superoxide. First, gene transfer transduces endothelium and adventitia, but does not transduce media of intact vessels. Because smooth muscle cells may be an important source of superoxide in these disease states, 16 gene transfer of SOD may fail to deliver enough SOD to the media to dismute the superoxide. This may be true even for extracellular SOD, which is released into the extracellular space. In contrast, NO is extremely effective in inactivation of superoxide, and gene transfer of eNOS may result in generation of a large amount of NO in response to acetylcholine. Thus, although we commonly think of superoxide inactivating NO, we suggest that generation of large amounts of NO inactivates superoxide, and thereby improves endothelium-dependent relaxation in the presence of superoxide in the vessel wall. The use of gene transfer approaches was critical to our understanding of this concept.
We have had little difficulty in constructing most recombinant viruses, but had enormous difficulty in constructing a virus that expresses iNOS. Our understanding is that other investigators have had similar difficulty, for reasons that are not entirely clear. In preliminary experiments, we made the predictable observation that gene transfer of iNOS impairs contraction of the carotid artery ex vivo, by generation of large amounts of NO. 19 A surprise, however, was that gene transfer of iNOS produces marked impairment of responses to acetylcholine. The impairment is rapidly reversed by inhibitors of iNOS, and may be related to generation of superoxide by iNOS. We speculate that in several disease states, impairment of responses to acetylcholine may be related to expression of iNOS in the vessel wall.
Potential Implications for Gene Therapy
We are optimistic that gene therapy may eventually be used to prevent vasospasm and stroke after SAH. Our dream is that, when a cerebral aneurysm is clipped after SAH, a neurosurgeon will administer a vector into the CSF to prevent cerebral vasospasm. The concept is attractive because there currently is no effective method to prevent cerebral vasospasm after SAH. The clinical problem is important because about 25% of deaths from stroke are the result of SAH with vasospasm. 20 Recently we have examined effects of gene transfer of CGRP after experimental SAH in rabbits. 21 Injection of blood into the CSF produces a reduction in diameter of the basilar artery of about 30%, as measured with digital subtraction angiography. After injection of a recombinant adenovirus that expresses preproCGRP, we found no constrictor response after SAH. On the basis of these prelim- 
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inary studies, it appears that it may be possible to prevent cerebral vasospasm after SAH with gene therapy.
Inhaled nitric oxide is used in the treatment of pulmonary hypertension. Gene transfer of eNOS to the pulmonary vascular bed of rats attenuates pulmonary vasoconstrictor responses to hypoxia. 22 Our collaborators have reported that gene transfer of eNOS attenuates pulmonary hypertension in response to fibrosis produced by bleomycin. 23 Furthermore, gene transfer of eNOS, together with a cGMP phosphodiesterase inhibitor, was more potent than eNOS alone, suggesting a novel approach to treatment of pulmonary hypertension. Our collaborators also used gene transfer of CGRP to inhibit pulmonary hypertension. 24 They found that pulmonary vascular remodeling and pressor responses to hypoxia in mice were attenuated by inhalation of an adenovirus that expressed CGRP. With recent emphasis on early treatment of pulmonary hypertension, and evidence that gene transfer may produce prolonged attenuation of pulmonary hypertension, the prospect of gene therapy for this lethal disease is certainly attractive.
The Future
What are some advances to look for in the next few years? A major breakthrough will occur when better vectors are available. Many vectors are currently available, including liposomes, adeno-associated virus, and lentivirus. Each of these vectors has the strong advantage of producing far less inflammation than adenoviruses, but each also has major limitations that have been summarized elsewhere, 25 and in our opinion make these vectors less attractive. The "gutted" (or helper-dependent) adenovirus 26 is a very promising vector, because it has the advantages of the adenovirus with reduced inflammatory response. Current limitations are that this virus is extremely difficult to prepare in high titer or large quantities.
An alternative to development of new adenoviral vectors would be to give a far lower dose of the currently available adenoviruses. The inflammatory response to an adenovirus is related to the dose of virus that is used, 27 and it may be possible to obtain excellent gene expression with little or no inflammatory response, when low doses of virus are given. Thus, we have used several approaches in attempts to enhance gene transfer to blood vessels. 28 -30 Among the approaches we have used, the most effective is coprecipitation of the virus with calcium phosphate. 30 Another area of gene transfer technology that is very promising is targeting of the virus to different receptors. In theory, it may be possible to reduce binding of the adenoviruses to their usual receptors and, instead, to target the virus to tissue-specific receptors in endothelium. With this approach, it might be possible to inject a virus intravenously, minimize extraction by the liver and other tissues, and target the vector to specific receptors or endothelium of regions of the circulation that are abnormal. Selection of an appropriate promoter may allow augmentation of expression in regions of vessels that have the greatest abnormalities (eg, atherosclerotic lesions). 31, 32 In addition to targeting the virus to specific receptors, it may also be possible to regulate expression of the virus with tissuespecific promoters or regulatable promoters. These areas of research are receiving substantial emphasis, but there is relatively little focus on these areas in cardiovascular applications of gene transfer.
Finally, it is enjoyable to think about other disease states that may be treatable by gene therapy. The current focus of gene therapy is untreatable diseases. It is possible, however, that eminently treatable diseases like hypertension and hypercholesterolemia may eventually be targets for gene therapy. 33, 34 If safe vectors can be developed, it would be extremely attractive to avoid problems associated with noncompliance of taking medications by giving an occasional intravenous injection of a vector. If one could give intravenous injections, perhaps with clearance of the vector by the liver and prolonged release of the gene product from the liver into the blood, it might be possible to obtain greater compliance and thus more effective treatment for common diseases. Thus, although the targets for gene therapy probably will remain narrowly focused for many years, it is possible that gene therapy may eventually achieve widespread value.
